TY - JOUR
T1 - Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients
T2 - A double-blind, randomized controlled trial
AU - Wynn, Jonathan K.
AU - Green, Michael F.
AU - Sprock, Joyce
AU - Light, Gregory A.
AU - Widmark, Clifford
AU - Reist, Christopher
AU - Erhart, Stephen
AU - Marder, Stephen R.
AU - Mintz, Jim
AU - Braff, David L.
N1 - Funding Information:
Support for this study came from a Veterans Affairs Merit Grant, the Department of Veterans Affairs VISN-22 Mental Illness Research Education Clinical Center (MIRECC), NIMH Translational Study Grant MH042228 (DLB) and an investigator-initiated grant from Janssen, FP. Medications for this study were provided by Janssen, FP and Eli Lilly.
PY - 2007/9
Y1 - 2007/9
N2 - Prepulse inhibition (PPI), whereby the startle eyeblink response is inhibited by a relatively weak non-startling stimulus preceding the powerful startle eliciting stimulus, is a measure of sensorimotor gating and has been shown to be deficient in schizophrenia patients. There is considerable interest in whether conventional and/or atypical antipsychotic medications can "normalize" PPI deficits in schizophrenia patients. 51 schizophrenia patients participated in a randomized, double-blind controlled trial on the effects of three commonly-prescribed antipsychotic medications (risperidone, olanzapine, or haloperidol) on PPI, startle habituation, and startle reactivity. Patients were tested at baseline, Week 4 and Week 8. Mixed model regression analyses revealed that olanzapine significantly improved PPI from Week 4 to Week 8, and that at Week 8 patients receiving olanzapine produced significantly greater PPI than those receiving risperidone, but not haloperidol. There were no effects of medication on startle habituation or startle reactivity. These results support the conclusion that olanzapine effectively increased PPI in schizophrenia patients, but that risperidone and haloperidol had no such effects. The results are discussed in terms of animal models, neural substrates, and treatment implications.
AB - Prepulse inhibition (PPI), whereby the startle eyeblink response is inhibited by a relatively weak non-startling stimulus preceding the powerful startle eliciting stimulus, is a measure of sensorimotor gating and has been shown to be deficient in schizophrenia patients. There is considerable interest in whether conventional and/or atypical antipsychotic medications can "normalize" PPI deficits in schizophrenia patients. 51 schizophrenia patients participated in a randomized, double-blind controlled trial on the effects of three commonly-prescribed antipsychotic medications (risperidone, olanzapine, or haloperidol) on PPI, startle habituation, and startle reactivity. Patients were tested at baseline, Week 4 and Week 8. Mixed model regression analyses revealed that olanzapine significantly improved PPI from Week 4 to Week 8, and that at Week 8 patients receiving olanzapine produced significantly greater PPI than those receiving risperidone, but not haloperidol. There were no effects of medication on startle habituation or startle reactivity. These results support the conclusion that olanzapine effectively increased PPI in schizophrenia patients, but that risperidone and haloperidol had no such effects. The results are discussed in terms of animal models, neural substrates, and treatment implications.
KW - Olanzapine
KW - Prepulse inhibition
KW - Risperidone
KW - Schizophrenia
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=34548160376&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34548160376&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2007.05.039
DO - 10.1016/j.schres.2007.05.039
M3 - Article
C2 - 17662577
AN - SCOPUS:34548160376
VL - 95
SP - 134
EP - 142
JO - Schizophrenia Research
JF - Schizophrenia Research
SN - 0920-9964
IS - 1-3
ER -